Labelling Mayo Clinic Pharmacy Technician 
Pharmacy Times
JUNE 16, 2025
The findings emphasize nemolizumab’s swift response in treating atopic dermatitis symptoms, along with its long-term effectiveness in prurigo nodularis, as demonstrated in the OLYMPIA open-label extension trial (NCT04204616). Mayo Clinic. Pharmacy Times. News release. June 6, 2025. Accessed June 16, 2025. News release.
Pharmacy Times
JUNE 23, 2025
This act…allowed a pathway for manufacturers to create a ‘copy’ of a licensed patent product to make it cheaper and more discounted,” Soefje, director of pharmacy cancer care services and associate professor of pharmacy at Mayo Clinic in Rochester, Minnesota, said at the HOPA conference.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JULY 7, 2025
1 DOORwaY 90 Study Results The approval was supported by data from the prospective, multicenter, open-label, single-arm DOORwaY 90 study that evaluated the safety and efficacy of Y-90 resin microspheres in individuals with unresectable HCC. Mayo Clinic. News release. July 7, 2025. Accessed July 7, 2025. Liver cancer.
Pharmacy Times
JUNE 9, 2025
Still, confusion remains over the role of pharmacy and therapeutics (P&T) committees in this process. Tichy, PharmD, MBA, vice chair of pharmacy formulary for Mayo Clinic, explained. This governance issue is a very hot topic,” Eric M.
Pharmacy Times
JULY 9, 2025
The FDA has approved an updated label with a new recommended titration dosing schedule for donanemab-azbt (Kisunla; Eli Lilly and Company) for once-monthly amyloid-targeting therapy for adults that experience early symptomatic Alzheimer disease (AD). million individuals in the United States aged 65 and older.
Pharmacy Times
JUNE 15, 2025
In the randomized, open-label, multicenter phase 3 NATALEE clinical trial (NCT05306340), ribociclib (Kisqali; Novartis) plus endocrine therapy, a nonsteroidal aromatase inhibitor (NSAI), significantly improved invasive disease-free survival among individuals with HR-positive (HR+) and HER2-negative (HER2-) early breast cancer.
Pharmacy Times
JULY 14, 2025
SHOW MORE The expanded instructions for use labeling expand on the Farawave and Farawave Nav Pulsed Field Ablation (PFA) catheters. Boston Scientific receives FDA approval for expanded labeling of FARAPULSE™ Pulsed Field Ablation System. Mayo Clinic. News release. July 7, 2025. Accessed July 7, 2025. Atrial fibrillation.
Expert insights. Personalized for you.
26 
Let's personalize your content